NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
With a background that includes executive leadership, team building, and handling complex corporate, licensing, and commercial transactions, Marc has demonstrated a keen ability to navigate healthcare’s complex regulatory and compliance landscape. His prior leadership positions with both public and private companies, uniquely positions him to contribute strategic insight to NantHealth's legal operations.
"Marc’s appointment to our executive team signifies a pivotal milestone in NantHealth's evolution. As our company continues to grow, our legal team's role becomes increasingly vital. With Marc's seasoned expertise and robust background, we're confident in our ability to navigate complex legal landscapes," remarked Dr.
With a distinguished track record of leadership and a penchant for fostering collaborative environments, Marc is poised to play a pivotal role in guiding NantHealth's legal strategies. His commitment to championing initiatives that enhance healthcare accessibility and efficiency underscores NantHealth's unwavering dedication to transformative change in the industry.
In his new role, Marc will collaborate closely with NantHealth's leadership team to further elevate the company's legal capabilities and drive forward its strategic vision. He will be involved in all facets of Eviti Connect®, NaviNet®, OpenNMS and NantHealth’s affiliated company, AirStrip®.
Marc holds a Bachelor of Arts degree from
About NantHealth, Inc.
NantHealth, a member of the
Forward Looking Statements
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to,
statements regarding the timing and effectiveness of the reverse stock split and the Company’s ability to maintain its listing on Nasdaq (including its ability to achieve or maintain the minimum bid price required by Nasdaq and to comply with other requirements for listing on Nasdaq). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current plans, objectives, beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the price and volume fluctuations in trading of the Company’s Common Stock, the potential adverse effect of the reduced number of shares outstanding following the reverse stock split on the liquidity of the Company’s Common Stock, potentially adverse Nasdaq decisions related to the listing of the Company’s Common Stock on the Nasdaq Capital Market. The Company undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423259598/en/
562-397-3639
jen@nant.com
Source: NantHealth, Inc.